Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christian Buske, MD
Coordinating Investigator Germany University Hospital Ulm
Study Director - Eva Kimby, MD
National Co-Coordinating Investigator - Sweden, Denmark, Norway Hematology and Internal Medicine Karolinska Institutet Stockholm Sweden
Principal Investigator - Garcia Sanz, MD
National Co-Coordinating Investigator - University Hospital Salamanca Spain
Principal Investigator - Maria da Silva, MD
National Co-Coordinating Investigator - Portuguese Institute of Oncology Portugal
Principal Investigator - Martin Dreyling, MD
National Co-Coordinating Investigator - Germany University Hospital Großhadern, Munich
Principal Investigator - Meletios Dimopoulos, MD
National Co-Coordinating Investigator - University of Athens School of Medicine Athens Greece
Principal InvestigatorKOL profile → - Pierre Morel, MD
National Co-Coordinating Investigator - Centre Hospitalier Schaffner France (Lens cedex)
Principal Investigator - Roman Hajek, MD
National Co-Coordinating Investigator - Department of Haematooncology Ostrava Czech Republic
Principal Investigator - Sylvie Chevret
Central Statistics (France)Department of Biostatistics and Medical Information,Hôpital Saint Louis, Paris
Study Chair - Veronique Leblond, MD
National Co-Coordinating Investigator - Groupe Hospitalier Pitié Salpêtrière France (Paris)
Principal Investigator - Wolfram Klapper, MD
Coordinator Pathology (Germany) Department of Pathology Kiel
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Hospital Ulm
Ulm, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2013
- Primary completion
- 30 Nov 2018
- Completion
- 30 Apr 2024
- Last update posted
- 13 May 2024
- Registered enrollment
- 202
- Registry id
- NCT01788020
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.